(REH-goh-RA-feh-nib)
Regorafenib works by blocking proteins that signal cancer cells to divide. It also blocks proteins that signal the growth of new blood vessels that tumors need to grow. Blocking these signals keeps cancer cells from growing and spreading to other parts of the body. Regorafenib is a type of targeted therapy drug called a kinase inhibitor. It is a small-molecule drug (a drug that can enter cells easily).
FDA label information for this drug is available at DailyMed.
Use in Cancer
Regorafenib is approved to treat:
- Colorectal cancer that has spread to other parts of the body. It is used in patients who have not gotten better with other treatments.
- Gastrointestinal stromal tumor that has spread or cannot be removed by surgery. It is used in patients whose cancer has not gotten better with imatinib mesylate and sunitinib malate.
- Hepatocellular carcinoma (a type of liver cancer). It is used in patients who have already been treated with sorafenib.
Regorafenib is also being studied in the treatment of other types of cancer.
More About Regorafenib
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Regorafenib – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Regorafenib – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
